Overview

Study of XL999 in Patients With Multiple Myeloma

Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Symphony Evolution, Inc.